NASDAQ · NXTCHealthcarePharmaceuticals

NextCure financials

$4.85−4.63%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$0.00$0.00$0.00$0.00—$22.4M$6.3M
Gross profit$0.00$0.00$0.00$0.00—$22.4M$6.3M
Gross margin—————100.0%100.0%
Operating income-$57.6M-$59.7M-$67.6M-$75.9M-$70.8M-$41.2M-$37.5M
Net income-$55.8M-$55.7M-$62.7M-$74.7M-$69.4M-$36.6M-$33.7M
Net margin—————−163.6%−531.5%
Diluted EPS$-19.65$-23.88$-27.00$-32.28$-30.12$-15.96$-25.80
EBITDA-$55.4M-$54.3M-$64.0M-$71.8M-$66.6M-$37.8M-$34.8M
Operating cash flow-$49.6M-$40.8M-$53.0M-$53.9M-$57.3M-$45.0M-$35.6M
Free cash flow-$49.6M-$41.3M-$53.8M-$56.0M-$59.6M-$52.1M-$39.0M
Diluted shares2.8M2.3M2.3M2.3M2.3M2.3M1.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$26.0M$27.7M$13.1M$26.6M$12.3M$32.8M
Short-term investments$15.8M$40.9M$95.2M$133.3M$207.3M$250.7M
Total debt$0.00$0.00$0.00$0.00$0.00$3.5M
Total assets$50.2M$80.9M$128.0M$184.2M$242.4M$306.6M
Total liabilities$15.2M$15.4M$13.6M$16.6M$9.0M$12.9M
Shareholders' equity$34.9M$65.5M$114.4M$167.5M$233.4M$293.7M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology